• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    NovoCure (NVDA) Could Be 69% Undervalued After Japan Pancreatic Cancer Approval

    Simply Wall St·10/07/2026 04:35:57
    Listen to the news

    NovoCure (NVCR) just picked up a fresh regulatory win in Japan, where the health ministry approved its Optune Pax device for unresectable locally advanced pancreatic cancer alongside standard chemotherapy.

    The Japan approval came during a weak period for NovoCure’s shares, with the 1-day share price return down 1.51% and the 7-day share price return down 6.38%, extending a 30-day share price decline of 16.56%. At the same time, the year-to-date share price return is 14.10% and the 1-year total shareholder return is 5.72%, which indicates momentum that has cooled recently rather than a clear upward trend.

    Scan beyond NovoCure with a curated set of oncology and healthcare-focused opportunities in our 34 healthcare AI stocks that focus on cancer treatment technology.

    NovoCure now trades at a steep discount to analyst targets after the Japan approval bump faded. Is that discount mispricing clinical progress, or is it a fair reflection of ongoing losses and execution risk?

    Most Popular Narrative: 69% Undervalued

    NovoCure closed at $14.97, while the most followed narrative pegs fair value near $48.93. This creates a large gap between the current price and expectations built on TTFields expansion and profitability forecasts.

    NovoCure's pioneering position in device-based, non-invasive therapy uniquely aligns with the increasing global demand for alternatives to chemotherapy and radiation. As aging populations increase cancer incidence, TTFields is described as being positioned to achieve significant adoption, supporting expectations for long-duration revenue growth and margin expansion.

    The company's balance sheet and cash management, together with efforts to improve operational efficiency and device miniaturization, are cited as factors that may reduce production costs and support broader patient adherence. According to this view, these elements suggest a potential path to profitability and sustained earnings that some investors see as relatively resilient to macroeconomic pressures.

    See why 3 investors see NovoCure as 69% undervalued.

    Result: Fair Value of $48.93 (UNDERVALUED)

    Still, NovoCure’s story requires nearly flawless execution. Any setback in reimbursement decisions or slower physician uptake in new indications could quickly undermine the bullish thesis.

    Find out about the key risks to this NovoCure narrative.

    Next Steps

    Conflicted by NovoCure’s regulatory progress and the mixed share price record? Act quickly, review the data for yourself, and weigh both sides through 3 key rewards and 1 important warning sign.

    Want more ideas beyond NovoCure?

    If NovoCure has sharpened your focus on opportunity and risk, do not stop here. Let the Simply Wall St Screener surface fresh ideas tailored to your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.